Market open

Sutro Biopharma/$STRO

14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX

About Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Ticker

$STRO
Trading on

Industry

Biotechnology

Employees

306

Sutro Biopharma Metrics

BasicAdvanced
$194M
Market cap
-
P/E ratio
-$1.73
EPS
1.17
Beta
-
Dividend rate
$194M
1.17
$6.13
$2.32
1M
3.091
3.008
15.879
22.356
-4.82%
-18.40%
-110.89%
1.043
1.74
1.74
-1.537
230.90%
-40.45%
39.33%
-15.20%

What the Analysts think about Sutro Biopharma

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Sutro Biopharma stock.

Sutro Biopharma Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sutro Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $STRO

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sutro Biopharma stock?

Sutro Biopharma (STRO) has a market cap of $194M as of December 11, 2024.

What is the P/E ratio for Sutro Biopharma stock?

The price to earnings (P/E) ratio for Sutro Biopharma (STRO) stock is 0 as of December 11, 2024.

Does Sutro Biopharma stock pay dividends?

No, Sutro Biopharma (STRO) stock does not pay dividends to its shareholders as of December 11, 2024.

When is the next Sutro Biopharma dividend payment date?

Sutro Biopharma (STRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Sutro Biopharma?

Sutro Biopharma (STRO) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.